Fig. 4

UM171a-triggered cross-presentation requires ROS production. A Representative diagram displaying the ETC complexes and their respective inhibitors. B Schematic diagram representing the experimental design of ETC inhibitor use along with UM171a. C Antigen presentation assay using ETCi co-treated with UM171a (upper panel) or added at day 3 during OVA pulsing. D Representative flow cytometry analysis of MitoSOX in MSCs co-treated with UM171a and Antimycin-A. The ETCi was added during the OVA pulsing period. The dashed line represents basal ROS levels before treatments. The dashed line represents the UM171a-induced MitoSOX signal. E Representative flow cytometry analysis of OVA uptake (left panel) versus OVA processing (right panel) in the absence or presence of Antimycin-A co-treatment. All experiments were repeated at least three times. The dashed lines represent the signal in the OVA-treated groups only. For panels in C, n = 6/group with *P < 0.05 and ***P < 0.001